News List

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E

USFDA approves KIT inhibitor Ayvakit (Avatinib)

CStone's partner Blueprint Medicines recently announced that the U.S. Food and Drug Administrati

Xofluza was approved in China

On April 29, 2021, Roche China announced that its innovative influenza drug Xofluza® (Mabaloxavir) h

Tagrisso approved in China in early lung cancer

AstraZeneca'sTagrisso(osimertinib) has been approved in China for the adjuvant treatment of pati

Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t

BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM

On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa

VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China

January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri

Progress in the development of new and efficient diabetes treatment drugs

Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.